The world is vulnerable and in search of novel cures for infectious viral diseases such as the flu and our current pandemic from COVID-19. Unlike vaccines that treat seasonal sickness, CytoAgents is decoding the underlying reasons for the life-threatening symptoms generated from a Cytokine Release Syndrome: the immune system’s reactive response to fight off viruses. 



We are currently experiencing the most severe global pandemic from Covid-19 in over 100 years. The industry is rushing to discover effective vaccines. CytoAgents’ leading product uses immunotherapy to reduce Cytokine Release Syndrome symptoms that lead to death.



According to the CDC, last year there were 23 million medical visits, 960,000 hospitalizations and 80,000 deaths in the US from influenza. 


New strains and combinations of influenza strains circulate every year. 



There is no therapy for influenza beyond the first 48 hours of influenza symptoms.



The excessive release of pro-inflammatory cytokines is called a cytokine storm. The cytokine storm has been implicated in the high morbidity and mortality rates seen with infection with Covid-19, different strains of influenza including subtypes H5N1 (avian flu) and H1N1 (swine flu), as well as with Severe Acute Respiratory Syndrome (SARS) caused by the SARS-CoV virus. 


Because the symptoms of influenza and all ‘influenza-like-illness’ can be associated with high levels of pro-inflammatory cytokines, the symptoms of all moderate and severe cases of influenza could be due to a cytokine storm. The cytokine storm can cause tissue damage and the accumulation of cell debris that can clog airways leading to a decrease in lung function and pneumonia.

The major strains currently in circulation are in (COVID-19?) the H1N1, H5N1, and H3N2 subtypes. It is unclear why some strains induce mild or severe cases of influenza in most people, but in other cases induce severe cases of influenza with devastating results. In the spring of 2009, a new influenza virus was identified. Originally called “swine flu”, the new virus has been named “2009 H1N1”.



CytoAgents is developing an immunotherapeutic product that solves the fundamental question: How do we cure patients who experience an extreme inflammation overreactive response to viruses?  


Shifting a paradigm in thinking about how viruses effect our bodies will radically alter how we treat patients. Rather than relying on vaccines and waiting for unique vaccines to be developed for each viral strain, we will have a universal treatment for any respiratory epidemic that comes along.


GP1681 is CytoAgents’ leading product. It addresses the unmet need and virus that is posing the greatest existential threat the world has seen in one hundred years. GP1681 has been in development for X years. CytoAgents has submitted an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for a treatment indication for Influenza, which will expand to Cornoavirus and Acute Respiratory Distress Syndrome. Safety profile here if there is one…



GP1681 will provide significant benefit to patients and our health care system:

  • Faster recovery times

  • Reduced number and length of hospital stays

  • Reduced intensity of respiratory symptoms

  • Lower death rates


2425 Sidney Street

Pittsburgh, PA 15203



Success! Message received.